Zhejiang Orient Gene Biotech Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Xiaoliang Fang

Amministratore delegato

CN¥907.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.6yrs
Proprietà del CEO	n/a
Durata media del management	7.6yrs
Durata media del Consiglio di amministrazione	7.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Aug 20

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

AMMINISTRATORE DELEGATO

Xiaoliang Fang (67 yo)

7.6yrs

Mandato

CN¥907,200

Compensazione

Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Xiaoliang Fang	GM & Director	7.6yrs	CN¥907.20k	Nessun dato
Jinhong Yu	Deputy GM & Financial Manager	7.6yrs	CN¥890.30k	0.078% CN¥ 4.9m
Pang Qi	Deputy General Manager	7.6yrs	CN¥729.60k	0.078% CN¥ 4.9m
Jinfeng Tan	Deputy General Manager	7.6yrs	CN¥834.60k	0.078% CN¥ 4.9m
Chunmei Zhong	Deputy General Manager	7.6yrs	CN¥737.30k	0.078% CN¥ 4.9m
Faying Xu	Deputy General Manager	7.6yrs	CN¥730.30k	0.078% CN¥ 4.9m

7.6yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di 688298 è esperto e expertise (durata media dell'incarico 7.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Xiaoliang Fang	GM & Director	7.6yrs	CN¥907.20k	Nessun dato
Jianqiu Fang	Chairman	7.6yrs	CN¥1.47m	Nessun dato
Bo Li	Independent Director	1.3yrs	CN¥33.70k	Nessun dato

7.6yrs

Durata media

45yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 688298 sono considerati esperti (durata media dell'incarico 7.6 anni).

Zhejiang Orient Gene Biotech Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.56 loss per share (vs CN¥0.55 loss in 3Q 2023)

Zhejiang Orient Gene Biotech Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.43 loss per share (vs CN¥0.41 profit in 2Q 2023)

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Zhejiang Orient Gene Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Full year 2023 earnings released: CN¥1.97 loss per share (vs CN¥10.26 profit in FY 2022)

Now 21% undervalued after recent price drop

Zhejiang Orient Gene Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥1.85 loss per share (vs CN¥10.26 profit in FY 2022)

Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥1.54 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥3.35 in 2Q 2022)

Zhejiang Orient Gene Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Upcoming dividend of CN¥2.00 per share at 4.0% yield

First quarter 2023 earnings released: CN¥0.30 loss per share (vs CN¥12.30 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥17.74 (vs CN¥29.29 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.84 (vs CN¥3.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.02 (vs CN¥13.14 in 2Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 33% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥4.37 (vs CN¥1.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥18.40 (vs CN¥3.96 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.89 (vs CN¥0.37 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥14.07 (vs CN¥0.91 in FY 2019)

New 90-day low: CN¥135

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day high: CN¥203

Investor sentiment improved over the past week

New 90-day high: CN¥177

Market bids up stock over the past week

Softlab9 Technologies Inc. Purchases Rapid Antigen COVID Testing Kits from Zhejiang Orient Gene Biotech Co. Ltd

New 90-day low - CN¥123

New 90-day high - CN¥260

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media